Literature DB >> 19126579

The role of IGF-1R in pediatric malignancies.

Su Young Kim1, Jeffrey A Toretsky, Daniel Scher, Lee J Helman.   

Abstract

The insulin-like growth factor (IGF) family consists of ligands (IGF-I, IGF-II, insulin), several receptors (including IGF-1R), and six binding proteins (IGFBP-1 through IGFBP-6). Members of this family regulate key cellular activities and they also play an important role in the development and progression of both adult and childhood cancers. Binding of a ligand to the receptor leads to its activation, followed by signal transduction along several pathways. In some childhood malignancies, IGF-1R can be activated by endocrine, autocrine, or paracrine mechanisms. Although mutations in IGF-1R have not been identified, this signaling pathway is upregulated in many childhood cancers. These findings have led to the development of a host of IGF-1R signaling modulators that are currently being tested in clinical trials. This review explores the role of IGF-1R in a range of childhood malignancies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19126579      PMCID: PMC2721475          DOI: 10.1634/theoncologist.2008-0189

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  66 in total

1.  Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors.

Authors:  J A Toretsky; S M Steinberg; M Thakar; D Counts; B Pironis; C Parente; A Eskenazi; L Helman; L H Wexler
Journal:  Cancer       Date:  2001-12-01       Impact factor: 6.860

2.  Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors.

Authors:  J A Toretsky; M Thakar; A E Eskenazi; C N Frantz
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

3.  Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells.

Authors:  D B O'Gorman; M Costello; J Weiss; S M Firth; C D Scott
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

4.  Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein.

Authors:  D Ayalon; T Glaser; H Werner
Journal:  Growth Horm IGF Res       Date:  2001-10       Impact factor: 2.372

Review 5.  Structure and function of the type 1 insulin-like growth factor receptor.

Authors:  T E Adams; V C Epa; T P Garrett; C W Ward
Journal:  Cell Mol Life Sci       Date:  2000-07       Impact factor: 9.261

6.  Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.

Authors:  Liang Cao; Yunkai Yu; Isaac Darko; Duane Currier; Linnia H Mayeenuddin; Xiaolin Wan; Chand Khanna; Lee J Helman
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

7.  Molecular characterization of pediatric gastrointestinal stromal tumors.

Authors:  Narasimhan P Agaram; Michael P Laquaglia; Berrin Ustun; Tianhua Guo; Grace C Wong; Nicholas D Socci; Robert G Maki; Ronald P DeMatteo; Peter Besmer; Cristina R Antonescu
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

8.  A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy.

Authors:  Chand Khanna; Jennifer Prehn; David Hayden; Ryan D Cassaday; Jana Caylor; Shevin Jacob; Seuli M Bose; Sung-Hyeok Hong; Stephen M Hewitt; Lee J Helman
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Altered expression of members of the IGF-axis in hepatoblastomas.

Authors:  S G Gray; T Eriksson; C Ekström; S Holm; D von Schweinitz; P Kogner; B Sandstedt; T Pietsch; T J Ekström
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

View more
  42 in total

Review 1.  Cancer cell signaling pathways targeted by spice-derived nutraceuticals.

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Bharat B Aggarwal
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

2.  Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.

Authors:  Zhenfeng Duan; Edwin Choy; David Harmon; Cao Yang; Keinosuke Ryu; Joseph Schwab; Henry Mankin; Francis J Hornicek
Journal:  Mol Cancer Ther       Date:  2009-07-28       Impact factor: 6.261

3.  Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study.

Authors:  Scott C Borinstein; Donald A Barkauskas; Mark Bernstein; Allen Goorin; Richard Gorlick; Mark Krailo; Cindy L Schwartz; Leonard H Wexler; Jeffrey A Toretsky
Journal:  Pediatr Blood Cancer       Date:  2013-10-31       Impact factor: 3.167

4.  New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.

Authors:  Kristina A Cole; John M Maris
Journal:  Clin Cancer Res       Date:  2012-03-16       Impact factor: 12.531

5.  PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.

Authors:  Berkley E Gryder; Marielle E Yohe; Hsien-Chao Chou; Xiaohu Zhang; Joana Marques; Marco Wachtel; Beat Schaefer; Nirmalya Sen; Young Song; Alberto Gualtieri; Silvia Pomella; Rossella Rota; Abigail Cleveland; Xinyu Wen; Sivasish Sindiri; Jun S Wei; Frederic G Barr; Sudipto Das; Thorkell Andresson; Rajarshi Guha; Madhu Lal-Nag; Marc Ferrer; Jack F Shern; Keji Zhao; Craig J Thomas; Javed Khan
Journal:  Cancer Discov       Date:  2017-04-26       Impact factor: 39.397

Review 6.  PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.

Authors:  Ipsita Pal; Mahitosh Mandal
Journal:  Acta Pharmacol Sin       Date:  2012-09-17       Impact factor: 6.150

7.  Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.

Authors:  Hemant K Bid; Cheryl A London; Jin Gao; Haihong Zhong; Robert E Hollingsworth; Soledad Fernandez; Xiaokui Mo; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2013-04-02       Impact factor: 12.531

Review 8.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

9.  Targeted Therapy of Ewing's Sarcoma.

Authors:  Vivek Subbiah; Pete Anderson
Journal:  Sarcoma       Date:  2010-10-31

Review 10.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.